Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Intangibles (2016 - 2025)

Iradimed (IRMD) has disclosed Intangibles for 12 consecutive years, with $4.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Intangibles rose 19.93% to $4.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.8 million, a 19.93% increase, with the full-year FY2024 number at $4.3 million, up 23.39% from a year prior.
  • Intangibles was $4.8 million for Q3 2025 at Iradimed, up from $3.4 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $4.8 million in Q3 2025 to a low of $1.1 million in Q3 2021.
  • A 5-year average of $2.7 million and a median of $2.8 million in 2022 define the central range for Intangibles.
  • Biggest YoY gain for Intangibles was 159.65% in 2022; the steepest drop was 18.35% in 2022.
  • Iradimed's Intangibles stood at $1.1 million in 2021, then soared by 159.65% to $2.9 million in 2022, then increased by 19.51% to $3.5 million in 2023, then increased by 23.39% to $4.3 million in 2024, then rose by 12.46% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Intangibles are $4.8 million (Q3 2025), $3.4 million (Q2 2025), and $3.3 million (Q1 2025).